StudyRareStudyRare

Limb-girdle muscular dystrophy

Log in to star

Last updated Nov 3, 2026

Log in to add personal notes on this page.

A young adult presents with progressive proximal weakness affecting hips and shoulders. CK is elevated. Genetic testing reveals a variant in a sarcoglycan gene.

Heterogeneous (>30 subtypes); the genes encode different muscle proteins, so the mechanism differs by subtype.

  • AD (LGMD D): rare; includes dominantly acting CAPN3 variants
  • AR (LGMD R): more common; sarcoglycans (SGCA, SGCB, SGCG, SGCD), calpain-3 (CAPN3), dysferlin (DYSF), others

Many genes give one picture, proximal weakness and dystrophic muscle, usually with a high CK, but each acts on a different protein. Three recessive groups can be recognized by staining the biopsy for the missing protein:

  • Sarcoglycans: the four proteins form one complex at the muscle membrane that steadies dystrophin's link to the dystroglycans. A variant in any one gene leaves all four deficient on staining, so staining shows a sarcoglycanopathy but not which gene. These are the usual cause of severe childhood-onset weakness that looks like Duchenne with normal dystrophin. Cardiomyopathy is common in beta, gamma, and delta forms and rare in alpha.
  • Calpain-3: a muscle-specific, calcium-activated protease that remodels the sarcomere. Most variants are recessive loss of function. A few, such as c.643_663del21, act dominantly, probably because active calpain-3 is a dimer and the abnormal protein pairs with the normal one and inactivates it. In 10% to 30%, a western blot shows normal amounts of a protein that may still be inactive, so a normal blot does not exclude the diagnosis.
  • Dysferlin: a membrane protein for calcium-driven membrane repair; loss-of-function variants leave very little at the membrane.
  • Proximal weakness (pelvic and shoulder girdle)
  • Variable onset and severity by subtype
  • Elevated CK
  • Some subtypes: cardiomyopathy, respiratory involvement
  • Elevated serum CK with proximal weakness prompts evaluation; EMG and muscle MRI support a myopathic pattern
  • Multigene LGMD panel (or broad neuromuscular panel) is the preferred confirmatory test given marked locus heterogeneity
  • Muscle biopsy with immunohistochemistry (sarcoglycans, dysferlin, dystrophin) when molecular testing is inconclusive
  • Physical and occupational therapy to preserve mobility; orthopedic management of contractures and scoliosis
  • Cardiac surveillance (ECG, echocardiogram) for subtypes with cardiomyopathy or conduction disease
  • Pulmonary function monitoring with respiratory support as needed in subtypes with diaphragmatic involvement
  • Multidisciplinary neuromuscular care; genetic counseling reflecting subtype-specific inheritance (AR vs AD)

"LGMD = young adult with progressive weakness in shoulders and hips": Think of LGMD when you see proximal weakness affecting both the pelvic and shoulder girdle (vs Becker, which predominantly affects hips). LGMD is an example of locus heterogeneity (>30 genes cause the same clinical phenotype).